Roche boosts drug profile with US merger
Swiss drug company Roche has announced it is buying United States-based Anadys Pharmaceuticals for $230 million ($257 million).
Basel-based Roche said on Monday that the merger would boost its portfolio of drugs to treat hepatitis C. Anadys has developed an oral drug called Setrobuvir that is currently being trialed for treatment of chronic hepatitis C infections.
Roche said it would pay $3.70 per share, a premium of more than 250 per cent on Anadys's closing price on Friday.
Anadys CEO Steve Worland said the merger provided “the best chance of success for the new potential treatments our team has been dedicated to developing”.
Roche is a world leader in cancer treatments, diagnostics and diabetes treatments.
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at firstname.lastname@example.org.